SCHEMBL14980281

SCHEMBL14980281

CN1CCN(CCOCCOCCOCCO)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.51
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 3/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HTR7 P34969 2/20 0.43
ABCB11 O95342 1/20 0.42
CHRM2 P08172 1/20 0.42
ADRA2A P08913 1/20 0.42
DRD2 P14416 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
DRD4 P21917 1/20 0.42
HRH2 P25021 1/20 0.42
HTR2A P28223 1/20 0.42
ADRA1A P35348 1/20 0.42
HRH1 P35367 1/20 0.42
DRD3 P35462 1/20 0.42
OPRK1 P41145 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18353898 1.00 HTR1A (0.51) HTR1AKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL1097993 0.98 HTR1A (0.53) HTR1AKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL31305373 0.91 MEN1 (0.55) HTR1AKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL31305372 0.91 MEN1 (0.55) HTR1AKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL18024036 0.90 HTR1A (0.46) HTR1AKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL8966405 0.89
SCHEMBL4905012 0.89 HTR1A (0.54) HTR1AKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL20231213 0.88 ALDH1A1 (0.46) HTR1AKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL2512123 0.87 ALDH1A1 (0.55) KDM4EALDH1A1MEN1KMT2ADRD3
SCHEMBL21940818 0.86 HTR1A (0.50) HTR1AKDM4EALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790499-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
US-9278987-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2016-03-08 US disclosed
US-20140330006-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF SAREPTA THERAPEUTICS, INC. (US) 2014-11-06 US disclosed
WO-2013074834-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF SAREPTA THERAPEUTICS, INC. (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140330006-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF RTCB, NSUN3, NSUN2 HTR1A 4675/4885KDM4E 3565/4885ALDH1A1 3163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.